oncolytic


Also found in: Medical, Encyclopedia, Wikipedia.

oncolytic

(ˌɒŋkəˈlɪtɪk)
adj
(Biology) absorbing or destroying tumours
References in periodicals archive ?
Merck known as MSD outside the United States and Canada, and Viralytics Limited today announced that the companies have signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers by way of a scheme of arrangement (Scheme) for AUD 1.
M2 EQUITYBITES-January 23, 2018-SillaJen expands partnership with ABL Europe for oncolytic virus therapies JX-594 & JX-970
M2 PHARMA-January 23, 2018-SillaJen expands partnership with ABL Europe for oncolytic virus therapies JX-594 & JX-970
Oncolytic viruses have the power of directly lysing cancer cells, and they also free tumor-specific neoantigents, as they can indirectly act as a cancer vaccine.
Transgene and Randox have entered into a collaboration to combine their technologies and develop multifunctional oncolytic immunotherapies.
Our results are the first to provide insight into ways of targeting multiple brain metastatic deposits with stem cell-loaded oncolytic viruses that specifically kill dividing tumor cells.
Virttu is focused on the development of oncolytic virus therapy for treatment of cancer.
History of oncolytic viruses: genesis to genetic engineering.
Oncolytic viruses, with their long history of experimentation, have been deemed to be a key player in the future treatment of gliomas.
Medivate Partners has closed a USD12 million investment in Sillajen, a global oncolytic immunotherapeutic firm currently in Phase III multi-national clinical development in US, Europe and Asia, the company said.
Treatment with the oncolytic immunotherapy talimogene laherparepvec (T-VEC) resulted in significantly longer rates of durable response and overall response, compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF), according to results from the phase III OPTiM trial reported in the Journal of Clinical Oncology.
VSV-GP is a highly potent oncolytic virus that carries the surface protein from the lymphocytic choriomeningitis virus (LCMV).